Small Molecule
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
80
NCT06998719
Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC
Phase: Phase 2
Role: Lead Sponsor
Start: Jul 31, 2025
Completion: Dec 31, 2027
Loading map...